List view / Grid view
The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
According to scientists, maternal cells act as a reservoir for Zika, enabling the virus to pass from mother to foetus during pregnancy.
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
Research suggests heparin could be repurposed for COVID-19 because it can bind to the SARS-CoV-2 Spike protein and prevent the virus from infecting cells in vitro.
In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.
28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery
In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.
The database could save substantial resources for those wanting to do pre-clinical studies of interventions for age-related diseases, said scientists.
Researchers have identified a new compound that improved responses to insulin and treated diabetes in obese mouse models.
![A microscopy image of Leptospira bacteria [Credit: Wunder et al. (CC BY 4.0)].](https://www.drugtargetreview.com/wp-content/uploads/Leptospira-bacteria.jpg)
A single vaccination with a mutated Leptospira bacteria prevented rodent models from developing leptospirosis, the most fatal type of zoonotic disease worldwide.
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
Identifying allosteric modulators and biased agonists for clinically relevant GPCRs. Case Studies using Eurofins Discovery’s GPCR product solutions.
Researchers have developed a novel CAR T-cell therapy for neuroblastoma which uses gating to limit toxicity and T-cell exhaustion.
A new study shows that upregulating the activity of the ACE2 signalling pathway in kidney cancer cells enhances the effects of clinically used treatments.
